

Published: August 31, 2022

Citation: Reinhard R, Biermann N, et al., 2022. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), Medical Research Archives, [online] 10(8). <https://doi.org/10.18103/mra.v10i8.2840>

Copyright: © 2022 European Society of Medicine. This is an open- access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI
<https://doi.org/10.18103/mra.v10i8.2840>

ISSN: 2375-1924

REVIEW ARTICLE

Breast Implant Anaplastic Large Cell Lymphoma (BIA-ALCL): A Systematic Review and Case Report Regarding Incidence and Pathology Workup

Ruben Reinhard*¹, Niklas Biermann*¹, Britta Kuehlmann², Lukas Prantl¹

¹ University Center for Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital Regensburg, Germany

² Division of Plastic, Reconstructive Surgery, Department of Surgery, Stanford University, USA

*contributed equally

Correspondence: Ruben.Reinhard@klinik.uni-regensburg.de

ABSTRACT

Background: Breast implant–associated anaplastic large cell lymphoma (BIA ALCL) is a rare indolent yet lethal disease. Recently the WHO accepted it as an individual new entity. Since then national and international registries have attempted to collect epidemiological data, but incidence rates vary strongly. The aim of this article is to provide an update on the status of the national BIA-ALCL registries and identify pitfalls alongside the current collection and diagnostic algorithm.

Methods: A systematic review of the literature was performed and epidemiological data from national registries were compared. Furthermore a case report of a false positive diagnosis was added and the pitfalls alongside the diagnostic algorithm was worked out.

Results: The comparison of national registries revealed significant differences in the collected data. Mean start of the registries was 2014, median 2015. Reporting of BIA-ALCL cases is mandatory except in two countries. Capture rates vary between 0-100%. Incidence rates range from 0.0 up to 8.9 per million implant years. The number of deaths does not correlate with the number of implants or the total population. The very same strains of CD30 can be interpreted differently.

Conclusion: Comparing epidemiologic data revealed significant differences among national registries. In particular, non-published sales data of breast implants and non-mandatory recording of the disease lead to an overall underreporting of cases. Therefore, the incidence rates still cannot be compared uniformly. Furthermore the definition of CD30 straining intensity should be standardized and adjusted in the guidelines.

Introduction

BIA-ALCL is a rare type of Non-Hodgkin Lymphoma (NHL) which is associated with mostly texturized breast implants¹.

Incidents are on the rise and even though it is still a rare disease with 733 reported and approximately 993 cases in total, it is expected to increase even further^{2 3 4 5}.

In 1997, it was first suggested that there might be a link between breast implants and a new form of T-cell lymphoma⁶. Since only single cases were known, it was initially difficult to understand the pathogenesis and to derive therapeutic recommendations. This changed with first cohort studies⁷ that provided epidemiologic information, revealed risk factors, and improved recommendations in suspect cases.

Hence in 2011, the FDA issued a safety communication warning of increasing evidence linking implants to a new form of ALCL⁸. Subsequently some national breast implant registries were established e.g. the swedish Bröstimplantatregistret⁹.

It has been the subject of repeated discussion, particularly since its recognition as a separate entity by the WHO in 2016¹⁰. Since then, the

number of annually reported cases has increased significantly. This eventually led to the possibility of more precise diagnostic and therapeutic recommendations of this rare, indolent yet lethal disease¹¹. Today an interdisciplinary approach with early, specific detection proved to be associated with an excellent prognosis¹². The diagnostic pathway now consists of clinical presentation, medical imaging, and pathologic workup¹³. In most cases a T-cell typical surface pattern was found and CD30 was consistently strong positive, with negative testing for ALK¹⁴.

Despite these diagnostic improvements, the notification algorithm and follow-up after breast implant placement within registries is inconsistent. Non-mandatory reporting and opt-out regulations lead to an underreporting and unreleased sales data of breast implants impede the calculation of an exact incidence of the BIA-ALCL. Additionally, non-standardized immunohistochemical staining analysis may lead to false negative results.

To underline the importance of breast implant registries and outline the diagnostic workup, we systematically reviewed the literature and present a case report regarding the immunohistochemical staining process.




Figure 1 PRISMA 2020¹⁵

Country	Breast implant registry	Breast Augmentation in Public practice	Breast Augmentation in Private practice	Registry start	Registry mandatory	Report of BIA ALCL cases mandatory	BIA ALCL cases Total	BIA ALCL Deaths	Breast augmentation/ ISAPS Year	Total population	Incidence per 1.000.000 implant years
Australia	Australian Breast Device Registry	75 - 100% ¹⁶	75 - 100% ¹⁶	2014 ¹⁶	opt out ¹⁷	No ¹⁸	112 ¹⁷	4 ¹⁹	17 553 ²⁰	25 877 751 ²¹	
Denmark	Danish Registry for Plastic Surgery	100% ¹⁶	50 - 70% ¹⁶	1999 ¹⁶	No ¹⁶	Yes ²²	9 ²²	0 ²²	N.A.	5 873 420 ²³	
France	French breast implant registry	25 - 50% ¹⁶	0 - 25% ¹⁶	2018 ¹⁶	N.A.	Yes ²²	86 ²²	4 ²²	53 938 ²⁴	67 827 000 ²⁵	
Germany	Implantat register Deutschland	N.A.	N.A.	2024 ¹⁶	Mandatory ¹⁶	Yes ²²	30 ²⁶	0 ²²	67 634 ²⁷	83 222 442 ²⁸	East Bavaria: 0.0 ²⁹
Italy	National Breast Implants Registry	0 - 25% ¹⁶	0 - 25% ¹⁶	2017 ¹⁶	No ¹⁶	Yes ²²	79 ³⁰	2 ³⁰	39 276 ²⁷	58 983 122 ³¹	3.5 ³²
Netherlands	Dutch National Breast Implant Registry	100% ¹⁶	94% ¹⁶	2015 ¹⁶	opt out ¹⁶	Yes ²²	65 ²²	2 ²²	N.A.	17 618 135 ³³	8.9 ^{34,29}
Spain	Sistema de Registro Español de Implantes de Mama	0 - 25% ¹⁶	0 - 25% ¹⁶	2013 ¹⁶	opt out ¹⁶	Yes ²²	40 ²²	1 ²²	44 406 ²⁷	47 385 107 ³⁵	
Sweden	Bröst implantat registret of Sweden	100% ¹⁶	85% ¹⁶	2014 ¹⁶	opt out ¹⁶	Yes ²²	8 ³⁶	2 ²²	1 908 ²⁷	10 379 295 ³⁷	
United Kingdom	Breast and Cosmetic Implant Registry	75 - 100% ¹⁶	50 - 75% ¹⁶	2016 ¹⁶	opt out ¹⁶	Yes ²²	83 ³⁸	1 ²²	36 930 ²⁴	67 081 000 ³⁹	
United States of America	National Breast Implant Registry	N.A.	0 - 25% ¹⁶	2018 ¹⁶	opt out ¹⁶	No	384 ²²	12 ⁴⁰	371 997 ²⁷	331 893 745 ⁴¹	2.03 ^{42,29} 1.7 - 2.5 ^{42,29} 14.6 ^{29,7} 45.1 ^{29,43}

Table 1 Overview of breast implant Registries




Table 2 Coleman Methodology Score

Material and Methods

The literature research was conducted according to the principles of Evidence-Based Practice (EBP) in a sequential approach. Guidelines of national and international standard were discovered searching the databases of the "Guidelines International Network⁴⁴" and National Guideline Clearinghouse⁴⁵.

A systematic review of the literature was then conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines⁴⁶. The databases of PubMed has been comprehensively searched for meta-analysis, systematic or narrative reviews and primary clinical studies. The search interval included

data until 28.02.2022 using various connections of the keywords "ALCL*" in combination with either "incidence"[All Fields] AND "breast"[All Fields] AND "implant"[All Fields].

Articles published in other languages than English or German have been excluded, yielding 306 relevant studies. Subsequent primary screening included the title and abstract of each manuscript. Studies without an abstract were excluded and the full text was obtained if the abstract did not allow finding the defined inclusion or exclusion criteria. Strict care was taken to consider only epidemiological studies. Studies primarily investigating the clinical diagnosis and operative procedure were excluded.

To reduce selection bias the abstracts to all articles were read and reviewed independently by the authors. According to their relevance the whole article was close read and subsequently assessed for eligibility and excluded respectively.

To define the quality of the studies, the Coleman Methodology Score (CMS) was utilized to all original articles. It assesses the scientific quality using 10 criteria, giving a total score ranging between 0 and 100 points. With 100 indicating a small chance for various biases and confounding factors. The final score can be defined as excellent (85 to 100 points), good (70 to 84 points), fair (50 to 69 points), and poor (< 50 points).

Results

Out of 307 studies, 306 clinical studies have been included. 212 studies have been excluded according to the screening process and 47 full-text articles were assessed for eligibility. Subsequently, 20 studies have been excluded after full-text analysis due to the exclusion criteria (Fig.1).

We found 27 clinical studies and reviews describing the incidence and notification requirements or algorithm of the BIA-ALCL (Fig.1).

Clinical evidence ranged from level II-IV according to the Oxford Centre for Evidence-Based Medicine. According to the CMS scoring system 14 studies revealed a poor, 7 studies a fair, 3 studies a good and 3 an excellent methodology.

Table 1 is an overview of the current breast implant registries. The mean start of the registries was 2014, the median 2015. According to Bargon et al. seven out of ten countries have a better registration coverage for public hospitals than in private clinics¹⁶. Six of nine countries claim up to 100% registration coverage for the public sector, in comparison to only three of ten countries with a private clinic coverage of over 90% (Tab.1).

At the time of publication, the German breast implant registry is not yet online. Starting in 2024, it is expected to be the first mandatory registry for public and private hospitals. Thus, a national 100% coverage rate for private and public clinics is to be achieved. Patients, clinics and health insurance companies are obligated to report to the database. Until now reporting rates of all countries and registries vary and in most cases funding of the registries is not sustainable secured.

Worldwide, 36 people have died from BIA-ALCL to date⁴⁰. The number of deaths does not correlate with the number of implantations. For example, four people died from BIA-ALCL in both Australia and France, while three times as many breast implants were implanted in France.

There is also no correlation between the implantation rate and the detected cases. Comparing Spain and Italy with similar annual implantation rates, almost twice as many cases were found in Italy.

There are also differences in the countries that have not yet suffered any deaths. Neither in Germany nor in Denmark, a fatal case has been reported with 30 and nine overall cases overall cases respectively.

Incidence rates range from 0.0 per million implant years in Germany up to 8.9 in the Netherlands.

Case Presentation

A 44-year-old woman carrying the BRCA-2 mutation, underwent total mastectomy and immediate reconstruction with texturized implants (MENTOR 375cc texturized CPG 322 Gel Breast). Postoperative she developed a seroma on the right side and got revised (MENTOR Cohesive III 375cc medium light-moderate plus profile).

One year past surgery a control MRI detected a seroma surrounding her left implant. The fluid with signs of chronic inflammation in the cytological examination was drained repeatedly for another year, when she finally decided to change both implants for a new smooth variant (MENTOR Cohesive I 350cc smooth round submuscular). Postoperative, pathology analysis of both capsules showed a complete resected BIA-ALCL infiltration on the right side. Further radiologic examinations were made but found no additional signs of malignancy. Therefore, a consensus conference recommended no further therapy. Uncertain whether this was correct, she decided to get a second opinion.

She was presented to us one-month past surgery with increasing pain in both breasts, axilla, and back, as well as long-lasting retrosternal pressure. The implants showed medial rippling and lateral movability on light pressure. The radiologic imaging was re-evaluated and additional CEUS-sonography and PET was taken. Increased lymph nodes and 3° capsular fibrosis, as well as capsule residues and a seroma surrounding both implants were found in the MRI scan.

According to current guidelines⁴⁷, we removed the implants, performed en-bloc capsulectomy⁴⁸, and resected the suspect lymph nodes. Pathology evaluation of the specimens showed activated medium sized, mildly CD30 positive and ALK-1 negative cells, but no typical signs of malignancy such as CD30 positive blast clusters.

For reference, the initial positive probes were reevaluated by two additional, independent pathology institutes. This time however, the

histological description as well as the diagnosis were not confirmed, as the CD30 intensity was described as lightly expressed. So according to international recommendations⁴⁹ further analyzations were made. Including the determination of T-cell-clonality by using multiplex-

PCR and TCR-gamma/beta-receptor rearrangement analysis. Additional markers such as negative Ki67 and similar activity of CD3 to CD5 in activated T-cells were found confirming the rejection of the initial BIA-ALCL diagnosis⁵⁰.




Figure 2




Figure 3

Fig. 1 and 2: pathology typical case of a BIA-ALC.

Haematoxylin and eosin (H&E) stain of a capsule biopsy with clearly discernible atypical blast, some of them with characteristic horse-shoe shaped nuclei (hallmark cells) (courtesy of Prof. G. Ott, Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart).




Figure 3




Figure 4

Figure 3-4 Two pictures of our case.

Low intensity, single spread CD30 pattern but no signs of lymphoid blasts.

Figure 4 Immunohistochemistry of a light positive but dense area of CD30. Typical pattern of CD30 positive blasts in lymph follicles (provided with the kind support of Dr. Utpatel, Department of Clinical Pathology, University Hospital Regensburg)

Discussion

We systematically reviewed the literature up on the incidence of BIA-ALCL through breast implant registries and outlined the importance of a standardized pathology workup with a case report. We found that the incidence strongly varies and the calculation itself is challenging. This is due to the varying transmission rates, on the other due to the heterogeneity of the collected units e.g. person and implant years.

Additionally, unreleased sales data of breast implants account this mathematical uncertainty. Furthermore, the reporting rates of breast implant placement through breast implant registries yielded between 0% and 100% in public and private practices, respectively¹⁶. The reason for this heterogeneity lies within the political setting of these registries as most countries use opt-out systems leaving the reporting option to the surgeon. Even in Sweden with a 100% reporting rates in public and

85% in private clinics, the registered implants reach only 65%, possibly due to the higher number of breast augmentations in private clinics³⁶. A similar situation is found in the United Kingdom, where up to 100% of the implants are registered in the public sector but an estimated of only 55% of all implants are thereby captured⁵¹.

Again, the high number of breast augmentations in private clinics possibly accounts for the missing data considering the opt-out policy. Amongst other reasons this leads to an underreporting of cases as a comparison of the countries exemplifies. Australia reported a total of 112 cases over 25 million inhabitants⁵², while the United States found only 384 cases with 330 million inhabitants³⁸, depicting a strong percental difference. Consequently standardized and legal binding registries will be the only way to acquire international comparable data⁵³ and contribute to the pathophysiology including genetic predisposition and implant surface texture^{48,54}.

Another reinforcing factor for underreporting and low numbers of BIA-ALCL are uncertainties within the pathological work up. As our case report offers a clear view on the diagnostic pathway and pitfalls alongside. Mistakes can already occur in the collection of the samples, obtaining the cytology, or taking the capsule tissue. According to the 2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of BIA - ALCL⁵⁵ the diagnostic algorithm consists of four stages. Detection of suspect symptoms, clinical imaging, biopsy and pathological workup.

Clinically, there is usually a unilateral or bilateral seroma, occurring between one and ten years after implantation⁴². Ultrasound or MRI is used to detect solid or fluid forms of the disease. Finally, biopsy or fineneedle aspiration of the fluid or tissue is performed followed by the pathological workup. There is still no recommendation on where and how many samples should be taken and whether and how

much of the capsule should be excised. The following histological workup includes cytology, flow cytometry of T-cell clones and immunohistochemistry of CD30⁵⁶ and further differentiation markers⁵⁷. Especially the absence of ALK should be mentioned. CD30 positivity and ALK negativity alone are not sufficient for the diagnosis. Cluster differentiation and the experience of a hematopathologist is necessary.^{57,55}

As described above the CD30 intensity of the very same paraffin blocks was interpreted differently by two independent pathological institutes. This led to two diametrically different diagnosis.

Consequently the question should be raised of whether the CD30 intensity could be quantified and standardized objectively⁵⁸. Lymphoma supporting results have so far been described as highly intense^{59, 60} in contrast to the light to moderate description in this case. Taking the density of CD30 during chronic infections into account, a distinction between infection and lymphoma might be possible.

Conclusion

The BIA-ALCL is a rare disease whose incidence is difficult to collect reliably. Unreleased sales data of breast implants, non-mandatory reporting to public health departments and opt-out regulations for breast implant registries lead to an underreporting of cases. Furthermore, this article should raise awareness to the importance over the interpretation of CD30 intensity as the current definition leaves room for false-positive results. The primary analysis will be morphological, and we strongly recommend that cytopathologists or breast pathologists who may initially receive such specimens work closely with hematopathology colleagues in large centres with high experience.

Conflict of interest

The authors have no conflicts of interest to declare. The authors did not receive funding for this article.

References

1. Health, Center for Devices and Radiological. Breast Implants - Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses. Published January 10, 2021. Accessed January 10, 2021. <http://wayback.archive-it.org/7993/20171115053750/https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm#executivesummary>
2. McCarthy CM, Loyo-Berrios N, Qureshi AA, et al. Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): Initial Report of Findings, 2012-2018. *Plast Reconstr Surg.* 2019;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):65S-73S. doi:10.1097/PRS.0000000000005571
3. Clemens MW, Brody GS, Mahabir RC, Miranda RN. How to Diagnose and Treat Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Plast Reconstr Surg.* 2018;141(4):586e-599e. doi:10.1097/PRS.0000000000004262
4. U. S. Food and Drug Administration. Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Published January 9, 2021. <https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma>
5. American Society of Plastic Surgeons. BIA-ALCL Physician Resources. Published March 3, 2021. Accessed March 3, 2021. <https://www.plasticsurgery.org/for-medical-professionals/health-policy/bia-alcl-physician-resources>
6. Keech JA, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. *Plast Reconstr Surg.* 1997;100(2):554-555. doi:10.1097/00006534-199708000-00065
7. Largent J, Oefelein M, Kaplan HM, Okerson T, Boyle P. Risk of lymphoma in women with breast implants: analysis of clinical studies. *Eur J Cancer Prev.* 2012;21(3):274-280. doi:10.1097/CEJ.0b013e328350b0ae
8. U.S. Food and Drug Administration. Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses. Accessed January 10, 2021. <http://wayback.archive-it.org/7993/20171115053750/https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm#executivesummary>
9. Lekander J. Årsrapport 2014 Bröstimplantatregistret - BRIMP. Accessed April 25, 2022. https://registercentrum.blob.core.windows.net/brimp/r/BRIMP_arsrapport_2014-HkemJ8JvXH.pdf
10. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* 2016;127(20):2375-2390. doi:10.1182/blood-2016-01-643569
11. Carty MJ, Pribaz JJ, Antin JH, et al. A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. *Plast Reconstr Surg.* 2011;128(3):112e-118e. doi:10.1097/PRS.0b013e318221db96
12. St Cyr TL, Pockaj BA, Northfelt DW, Craig FE, Clemens MW, Mahabir RC. Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management. *Plast Surg (Oakv).* 2020;28(2):117-126. doi:10.1177/2292550320925906
13. Kuehlmann B, Prantl L. Die Zeit ist reif für ein deutschlandweit verpflichtendes Brustimplantateregister - Pilotprojekt Brustimplantate Erhebungsbogen: (Need for a German Breast Implant Registry - Pilot Project Breast Implant Template). *Handchir Mikrochir plast Chir.* 2016;48(4):199-204. doi:10.1055/s-0042-111003
14. Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. *J Clin Oncol.* 2014;32(2):114-120. doi:10.1200/JCO.2013.52.7911
15. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71. doi:10.1136/bmj.n71
16. Bargon CA, Becherer BE, Young-Afat DA, et al. Moving breast implant registries forward: Are they FAIR and Functional? *J Plast Reconstr Aesthet Surg.* 2021;74(1):4-12. doi:10.1016/j.bjps.2020.10.001
17. Australian Breast Device Registry. 2020-ABDR-Annual-Report-FINALweb. Accessed April 24,

2022. <https://www.abdr.org.au/wp-content/uploads/2021/12/2020-ABDR-Annual-Report-FINALweb.pdf>
18. Therapeutic Goods Administration. BIA-ALCL: Information for health professionals. Published April 24, 2022. Accessed April 24, 2022. <https://www.tga.gov.au/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl>
 19. Therapeutic Goods Administration. Breast implants and anaplastic large cell lymphoma. Published April 24, 2022. Accessed April 24, 2022. <https://www.tga.gov.au/alert/breast-implants-and-anaplastic-large-cell-lymphoma>
 20. International Society of Aesthetic Plastic Surgery. ISAPS Global Survey Results 2018. Accessed April 24, 2022. <https://www.isaps.org/wp-content/uploads/2019/12/ISAPS-Global-Survey-Results-2018-new.pdf>
 21. Australian Bureau of Statistics. Population Clock. Accessed April 25, 2022. <https://www.abs.gov.au/ausstats/abs@.nsf/94713ad445ff1425ca25682000192af2/1647509ef7e25faaca2568a900154b63?OpenDocument>
 22. Scientific Committee on Health, Environmental and Emerging Risks. FINAL Opinion on the safety of breast implants in relation to anaplastic large cell lymphoma. Accessed April 25, 2022. https://ec.europa.eu/health/system/files/2021-04/scheer_o_018_0.pdf
 23. Statistics Denmark. Population at the first day of the quarter 2021 Q2. Published April 25, 2022. Accessed April 25, 2022. <https://www.dst.dk/en/Statistik/emner/borge/re/befolkning>
 24. International Society of Aesthetic Plastic Surgery. Global Survey_2019_Stand_2020.indd. Accessed April 25, 2022. <https://www.isaps.org/wp-content/uploads/2020/12/Global-Survey-2019.pdf>
 25. Institut national de la statistique et des études économiques. Demography - Population at the beginning of the month - France (including Mayotte since 2014) | Insee. Published April 25, 2022. Accessed April 25, 2022. <https://www.insee.fr/en/statistiques/serie/001641607>
 26. Bundesinstitut für Arzneimittel und Medizinprodukte. Möglicher Zusammenhang zwischen Brustimplantaten und der Entstehung eines anaplastischen großzelligen Lymphoms (ALCL). Published April 25, 2022. Accessed April 25, 2022. https://www.bfarm.de/SharedDocs/Risikoinformationen/Medizinprodukte/DE/Brustimplantate_ALCL_FDA.html
 27. International Society of Aesthetic Plastic Surgery. ISAPS-Global-Survey_2020. Accessed April 24, 2022. https://www.isaps.org/wp-content/uploads/2022/01/ISAPS-Global-Survey_2020.pdf
 28. Statistisches Bundesamt. Bevölkerung nach Nationalität und Geschlecht (Quartalszahlen). Published July 7, 2021. Accessed April 25, 2022. <https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Bevoelkerungsstand/Tabelle/liste-zensus-geschlecht-staatsangehoerigkeit.html>
 29. Prantl L, Gerken M, Zeman F, et al. Incidence of Anaplastic Large Cell Lymphoma and Breast-Implant-Associated Lymphoma-An Analysis of a Certified Tumor Registry over 17 Years. *J Clin Med.* 2020;9(5). doi:10.3390/jcm9051247
 30. Ministero della Salute. Protesi mammarie e Linfoma anaplastico a grandi cellule (ALCL). Published April 25, 2022. Accessed April 25, 2022. https://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=4419&area=dispositivi-medici&menu=vigilanza
 31. Istituto Nazionale di Statistica. Resident population by age, sex and marital status on 1st January 2022. Published April 25, 2022. Accessed April 25, 2022. <https://demo.istat.it/popres/index.php?anno=2022&lingua=eng>
 32. Campanale A, Spagnoli A, Lispi L, Boldrini R, Marletta M. The Crucial Role of Surgical Treatment in BIA-ALCL Prognosis in Early- and Advanced-Stage Patients. *Plast Reconstr Surg.* 2020;146(5):530e-538e. doi:10.1097/PRS.0000000000007240
 33. Centraal Bureau voor de Statistiek. Bevolkingsteller. Published April 25, 2022. Accessed April 25, 2022. <https://www.cbs.nl/nl-nl/visualisaties/dashboard-bevolking/bevolkingsteller>
 34. Boer M de, van Leeuwen FE, Hauptmann M, et al. Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. *JAMA Oncol.* 2018;4(3):335-341. doi:10.1001/jamaoncol.2017.4510

35. INE. INEbase / Demografía y población / Padrón. Población por municipios / Estadística del Padrón continuo / Últimos datos. Published April 24, 2022. Accessed April 25, 2022. https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736177012&menu=ultiDatos&idp=1254734710990
36. Swedish National Quality Register for Breast Implants. BRIMP-Annual-Report-2020. Accessed April 25, 2022. <https://registercentrum.blob.core.windows.net/brimp/r/BRIMP-Annual-Report-2020--SkgiRSNRXF.pdf>
37. Statistiska centralbyrån. Befolkningsstatistik. <https://www.scb.se/hitta-statistik/statistik-efter-amne/befolkning/befolkningens-sammansattning/befolkningsstatistik/pong/tabell-och-diagram/helarsstatistik--kommun-lan-och-riktet/folkmand-i-riktet-lan-och-kommuner-31-december-2020-och-befolkningsforandringar-2020/>
38. Ionescu P, Vibert F, Amé S, Mathelin C. New Data on the Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Eur J Breast Health*. 2021;17(4):302-307. doi:10.4274/ejbh.galenos.2021.2021-5-6
39. Office for National Statistics. Population estimates. Published April 25, 2022. Accessed April 25, 2022. <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/>
40. Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma. FDA. Published <time datetime="2020-08-20T14:08:39Z">Thu, August 20, 2020 - 14:08</time>. Accessed April 24, 2022. <https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma>.
41. U.S. Census Bureau. QuickFacts: United States. Accessed April 25, 2022. <https://www.census.gov/quickfacts/fact/table/US/PST045219>
42. Doren EL, Miranda RN, Selber JC, et al. U.S. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Plast Reconstr Surg*. 2017;139(5):1042-1050. doi:10.1097/PRS.0000000000003282.
43. Wang SS, Deapen D, Voutsinas J, et al. Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort. *Br J Haematol*. 2016;174(3):480-483. doi:10.1111/bjh.13779
44. GIN. Home Page - GIN. Published February 1, 2022. Accessed April 21, 2022. <https://g-in.net/>
45. Guidelines and Measures | Agency for Healthcare Research and Quality. Published April 21, 2022. Accessed April 21, 2022. <https://www.ahrq.gov/gam/index.html>
46. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med*. 2015;162(11):777-784. doi:10.7326/M14-2385
47. Lamaris GA, Butler CE, Deva AK, et al. Breast Reconstruction Following Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Plast Reconstr Surg*. 2019;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):51S-58S. doi:10.1097/PRS.0000000000005569
48. Tevis SE, Hunt KK, Clemens MW. Stepwise En Bloc Resection of Breast Implant-Associated Anaplastic Large Cell Lymphoma with Oncologic Considerations. *Aesthet Surg J Open Forum*. 2019;1(1):ojz005. doi:10.1093/asjof/ojz005
49. van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. *Leukemia*. 2003;17(12):2257-2317. doi:10.1038/sj.leu.2403202
50. Montgomery-Goecker C, Fuda F, Krueger JE, Chen W. Immunophenotypic characteristics of breast implant-associated anaplastic large-cell lymphoma by flow cytometry. *Cytometry B Clin Cytom*. 2015;88(5):291-293. doi:10.1002/cyto.b.21222
51. NHS Digital. Breast and Cosmetic Implant Registry - January 2020 to December 2020, Management Information - NHS Digital. Published April 25, 2022. Accessed April 25, 2022. <https://digital.nhs.uk/data-and-information/publications/statistical/mi-breast-and-cosmetic-implant-registry/2021>
52. U.S. Food and Drug Administration. Questions and Answers about Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). FDA. Published <time datetime="2021-03-16T10:09:10Z">Tue, March 16, 2021 - 10:09</time>. Accessed April 25, 2022.

- <https://www.fda.gov/medical-devices/breast-implants/questions-and-answers-about-breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl>.
53. Prantl L, Fritschen U von, Liebau J, et al. Konzept für ein nationales Implantatregister zur Verbesserung der Patientensicherheit. *Handchir Mikrochir plast Chir.* 2016;48(6):320-329. doi:10.1055/s-0042-118863
 54. Deva AK, Turner SD, Kadin ME, et al. Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. *Cancers (Basel).* 2020;12(12). doi:10.3390/cancers12123861
 55. Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). *Aesthet Surg J.* 2019;39(Suppl_1):S3-S13. doi:10.1093/asj/sjy331
 56. Collett DJ, Rakhorst H, Lennox P, Magnusson M, Cooter R, Deva AK. Current Risk Estimate of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Textured Breast Implants. *Plast Reconstr Surg.* 2019;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):30S-40S. doi:10.1097/PRS.0000000000005567
 57. Quesada AE, Medeiros LJ, Clemens MW, Ferrufino-Schmidt MC, Pina-Oviedo S, Miranda RN. Breast implant-associated anaplastic large cell lymphoma: a review. *Mod Pathol.* 2019;32(2):166-188. doi:10.1038/s41379-018-0134-3
 58. Jones JL, Hanby AM, Wells C, et al. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. *Histopathology.* 2019;75(6):787-796. doi:10.1111/his.13932
 59. Di Napoli A, Pepe G, Giarnieri E, et al. Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma. *PLoS One.* 2017;12(7):e0181097. doi:10.1371/journal.pone.0181097
 60. Das DK, Chowdhury V, Kishore B, Chachra K, Bhatt NC, Kakar AK. CD-30(Ki-1)-positive anaplastic large cell lymphoma in a pleural effusion. A case report with diagnosis by cytomorphologic and immunocytochemical studies. *Acta Cytol.* 1999;43(3):498-502. doi:10.1159/000331109